Results 191 to 200 of about 4,515 (264)

Unraveling the Mechanisms, Clinical Impact, Comparisons, and Safety Profiles of Slow-Release Therapies in Glaucoma. [PDF]

open access: yesPharmaceutics
Zeppieri M   +8 more
europepmc   +1 more source

Evaluation of Redispersibility between Original and Generic Drugs of Brinzolamide Ophthalmic Suspension

open access: bronze
Tokio Obata   +6 more
openalex   +2 more sources

Brinzolamide

Expert Opinion on Pharmacotherapy, 2008
Primary open-angle glaucoma is a multifactorial optic neuropathy characterized by the progressive loss of retinal ganglion cells and their axons. However, the primary risk factor is elevated intraocular pressure (IOP), which can damage the optic nerve head (ONH) and until now was the only treatable risk factor.
openaire   +3 more sources

Topical brinzolamide-induced ciliary body effusion with secondary angle closure and myopic shift

BMJ Case Reports
Here, we describe a rare case of drug-induced unilateral ciliary body effusion precipitated by topical brinzolamide, presenting acutely with pain, angle closure and myopic shift.
Chelsea Guymer, A. Galanopoulos
semanticscholar   +1 more source

A Suitable Chromatographic Method for Simultaneous Estimation of Brimonidine and Brinzolamide in Glaucoma Treated Dosage Form: Influence of its Greenness with Use of Green Metric Tools

Oriental Journal of Chemistry
In the present work, a RP-HPLC technique was used to separate the two drug moieties in simple run with the use of a Hypersil BDS C18 (100 mm x 4.6 mm; 5µ) P/N: 28105-104630 column and isocratic mobile phase with acetonitrile and 65:35 (v/v) 0.02M Octane ...
H. K. Kohli   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy